Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.8K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.8K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.3K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.3K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.8K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.8K
Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

30
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
30
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.2K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.2K
Epilepsy ll: Types01:22

Epilepsy ll: Types

54
Recurrent seizures, stemming from abnormal electrical activity in the brain, are the defining characteristic of epilepsy, a chronic neurological condition. Because seizure features vary greatly, epilepsy is classified using two systems: by seizure type and by epilepsy syndromes. These classifications enable clinicians to describe seizure patterns and select suitable treatment strategies.I. Classification by Seizure Type1. Focal EpilepsyFocal epilepsy begins in one hemisphere of the brain.
54

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human hepatic organoids for the analysis of human genetic diseases.

JCI insight·2017
Same author

Analysis of the influence of the transducer and its coupling layer on round window stimulation.

Acta of bioengineering and biomechanics·2017
Same author

New alkenylated tetrahydropyran derivatives from the marine sediment-derived fungus Westerdykella dispersa and their bioactivities.

Fitoterapia·2017
Same author

Capturing the Unconventional Metallofullerene M@C<sub>66</sub> by Trifluoromethylation: A Theoretical Study.

Chemphyschem : a European journal of chemical physics and physical chemistry·2017
Same author

Zika-Virus-Encoded NS2A Disrupts Mammalian Cortical Neurogenesis by Degrading Adherens Junction Proteins.

Cell stem cell·2017
Same author

Intravenous immune-modifying nanoparticles as a therapy for spinal cord injury in mice.

Neurobiology of disease·2017

Related Experiment Video

Updated: May 5, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.2K

Immune mechanisms in epileptogenesis.

Dan Xu1, Stephen D Miller, Sookyong Koh

  • 1Department of Microbiology-Immunology and Interdepartmental Immunobiology, Feinberg School of Medicine, Northwestern University Chicago IL, USA ; Department of Pediatrics, Division of Neurobiology, Children's Research Center, Lurie Children's Hospital of Chicago Chicago IL, USA.

Frontiers in Cellular Neuroscience
|November 23, 2013
PubMed
Summary

Immune responses drive epilepsy by creating a cycle of brain inflammation and seizure susceptibility. Targeting these immune pathways offers potential for new epilepsy therapies.

Keywords:
T lymphocytesastrocytesepilepsyepileptogenesisimmune responseinflammationmicrogliaseizure

More Related Videos

Preparing Undercut Model of Posttraumatic Epileptogenesis in Rodents
07:58

Preparing Undercut Model of Posttraumatic Epileptogenesis in Rodents

Published on: September 15, 2011

8.9K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

11.8K

Related Experiment Videos

Last Updated: May 5, 2026

Pentylenetetrazole-Induced Kindling Mouse Model
07:06

Pentylenetetrazole-Induced Kindling Mouse Model

Published on: June 12, 2018

34.2K
Preparing Undercut Model of Posttraumatic Epileptogenesis in Rodents
07:58

Preparing Undercut Model of Posttraumatic Epileptogenesis in Rodents

Published on: September 15, 2011

8.9K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

11.8K

Area of Science:

  • Neuroscience
  • Immunology
  • Pathology

Background:

  • Epilepsy affects 1% of the global population, with immune responses playing a key role in its development.
  • A positive feedback loop exists between brain inflammation and epileptogenesis, where seizures and injury exacerbate inflammation, increasing seizure susceptibility.
  • This inflammation can lead to neuronal hyperexcitability and breakdown of the blood-brain barrier.

Purpose of the Study:

  • To review the role of innate and adaptive immune responses in epilepsy pathogenesis.
  • To discuss human and animal studies elucidating the contribution of brain inflammation to epileptogenesis.
  • To propose immune mechanisms underlying epilepsy and consider targeted therapeutic strategies.

Main Methods:

  • Review of pre-clinical and clinical evidence on neuroinflammation and epilepsy.
  • Analysis of the roles of brain-resident immune cells and peripheral leukocytes.
  • Discussion of specific proinflammatory pathways involved in epileptogenesis.

Main Results:

  • Immune responses, including proinflammatory cytokines, are critical in seizure induction and epilepsy progression.
  • Both resident brain immune cells and infiltrating peripheral immune cells contribute to epileptogenesis.
  • Key inflammatory pathways implicated include IL-1R/TLR signaling, DAMPs, and the COX-2/prostaglandin pathway.

Conclusions:

  • Immune system activation is a significant factor in the development and progression of epilepsy.
  • Understanding these immune mechanisms provides a basis for developing novel, targeted therapies.
  • Targeting specific inflammatory pathways offers a promising avenue for future epilepsy treatment development.